Treatment of systemic sclerosis

Area of Science:

• Rheumatology
• Dermatology
• Pulmonology

Background:

• Scleroderma, or systemic sclerosis, lacks major therapeutic breakthroughs.
• New treatments are being investigated, including biologic agents and novel approaches to managing complications like Raynaud's phenomenon.

Purpose of the Study:

• To review recent advancements and ongoing research in scleroderma therapy and outcome measurement.
• To evaluate the efficacy and safety of emerging treatments for systemic sclerosis and its associated conditions.

Main Methods:

• Review of recent studies and clinical trials concerning scleroderma treatments.
• Comparison of different scleroderma classification systems and outcome measurement tools.
• Evaluation of treatments for systemic sclerosis, Raynaud's phenomenon, and interstitial lung disease.

Main Results:

• Interferon alfa and gamma show potential by reducing collagen synthesis.
• Photopheresis efficacy is debated; cyclosporine use is limited by renal toxicity.
• Diffuse and limited scleroderma classification correlates with disease severity; skin score is a reliable measure.
• High-resolution pulmonary CT aids early detection of lung disease.
• Iloprost is effective for vasospasm, but not all prostacyclin analogues.
• Radical microarteriolysis shows promise for refractory Raynaud's phenomenon.

Conclusions:

• While no major breakthroughs exist, ongoing research explores promising therapeutic targets like collagen synthesis.
• Standardized outcome measurements and reliable classification systems are crucial for scleroderma research.
• Early detection and management of complications, such as interstitial lung disease and Raynaud's phenomenon, are vital.